Document is current
Any future updates will be listed below
-
Authors
Kahraman, Sevim
De Jesus, Dario F https://orcid.org/0000-0001-8826-9095
Wei, Jiangbo
Brown, Natalie K https://orcid.org/0000-0002-9984-0135
Zou, Zhongyu
Hu, Jiang
Pirouz, Mehdi https://orcid.org/0000-0002-7439-6066
Gregory, Richard I
He, Chuan https://orcid.org/0000-0003-4319-7424
Kulkarni, Rohit N https://orcid.org/0000-0001-5029-6119
-
Funding
Funding for this research was provided by:
HHS | National Institutes of Health (R01 DK067536)
HHS | National Institutes of Health (UC4 DK116278)
HHS | National Institutes of Health (RM1 HG008935)
HHS | National Institutes of Health (K99 DK135927)
American Diabetes Association (7-21-PDF-140)
HHS | NIH | National Cancer Institute (R35CA232115)
HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (RC2 DK139552)
Diabetes Research Wellness Foundation (Endowed Chair)
Howard Hughes Medical Institute (Investigator)
- License Information
-
More Information
Article History
Received: 1 September 2023
Revised: 5 August 2024
Accepted: 13 August 2024
First Online: 25 September 2024
Disclosure and competing interests statement
: SK is an employee of Boehringer Ingelheim Pharmaceuticals, Inc. RNK is on the Scientific Advisory Board of Novo Nordisk, Biomea and Inversago Therapeutics. CH is a scientific founder, a member of the scientific advisory board and equity holder of Aferna Bio, Inc. and AccuaDX Inc., a scientific co-founder and equity holder of Accent Therapeutics, Inc., and a member of the scientific advisory board of Rona Therapeutics. RIG is a co-founder, scientific advisory board member, and equity holder of Redona Therapeutics. The Gregory lab receives or has received research funding from Sanofi, Astellas, and Ono. The authors declare no competing interests.
